297 related articles for article (PubMed ID: 26774534)
1. Finasteride or dutasteride for the pharmacological treatment for male lower urinary tract symptoms due to benign prostatic hyperplasia?
Alcántara-Montero A; Brenes-Bermúdez FJ
Actas Urol Esp; 2016 May; 40(4):268-9. PubMed ID: 26774534
[No Abstract] [Full Text] [Related]
2. Current Pharmacological Treatment for Male LUTS due to BPH: Dutasteride or Finasteride?
Pirozzi L; Sountoulides P; Castellan P; Presicce F; Lombardo R; Romero M; De Nunzio C; Tubaro A; Schips L; Cindolo L
Curr Drug Targets; 2015; 16(11):1165-71. PubMed ID: 25981606
[TBL] [Abstract][Full Text] [Related]
3. A 5-year retrospective analysis of 5α-reductase inhibitors in men with benign prostatic hyperplasia: finasteride has comparable urinary symptom efficacy and prostate volume reduction, but less sexual side effects and breast complications than dutasteride.
Kaplan SA; Chung DE; Lee RK; Scofield S; Te AE
Int J Clin Pract; 2012 Nov; 66(11):1052-5. PubMed ID: 23067029
[TBL] [Abstract][Full Text] [Related]
4. Effects of dutasteride on lower urinary tract symptoms: a prospective analysis based on changes in testosterone/dihydrotestosterone levels and total prostatic volume reduction.
Shigehara K; Miyagi T; Nakashima T; Izumi K; Kitagawa Y; Mizokami A; Koh E; Shimamura M; Namiki M
Aging Male; 2016 Jun; 19(2):128-33. PubMed ID: 26890877
[TBL] [Abstract][Full Text] [Related]
5. Intravesical Prostatic Protrusion as a Predicting Factor for the Adverse Clinical Outcome in Patients With Symptomatic Benign Prostatic Enlargement Treated With Dutasteride.
Yoshida T; Kinoshita H; Yoshida K; Mishima T; Taniguchi H; Yanishi M; Komai Y; Yasuda K; Sugi M; Matsuda T
Urology; 2016 May; 91():154-7. PubMed ID: 26826590
[TBL] [Abstract][Full Text] [Related]
6. Rates of prostate surgery and acute urinary retention for benign prostatic hyperplasia in men treated with dutasteride or finasteride.
Kuiper JG; Bezemer ID; Driessen MT; Vasylyev A; Roehrborn CG; Penning-van Beest FJ; Herings RM
BMC Urol; 2016 Aug; 16(1):53. PubMed ID: 27580700
[TBL] [Abstract][Full Text] [Related]
7. Effects of Withdrawing α1-Blocker from Combination Therapy with α1-Blocker and 5α-Reductase Inhibitor in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia: A Prospective and Comparative Trial Using Urodynamics.
Matsukawa Y; Takai S; Funahashi Y; Majima T; Kato M; Yamamoto T; Gotoh M
J Urol; 2017 Oct; 198(4):905-912. PubMed ID: 28499730
[TBL] [Abstract][Full Text] [Related]
8. Cost-Effectiveness of Combination Therapy Versus Monotherapy in Benign Prostatic Hyperplasia: A Colombian Experience.
Guevara-Cuellar CA; Parody-Rúa E; Garcia-Perdomo HA; Arenas-Duque A
Value Health Reg Issues; 2018 Dec; 17():174-182. PubMed ID: 30415110
[TBL] [Abstract][Full Text] [Related]
9. Comparing Clinical and Economic Outcomes Associated with Early Initiation of Combination Therapy of an Alpha Blocker and Dutasteride or Finasteride in Men with Benign Prostatic Hyperplasia in the United States.
DerSarkissian M; Xiao Y; Duh MS; Lefebvre P; Swensen AR; Bell CF
J Manag Care Spec Pharm; 2016 Oct; 22(10):1204-14. PubMed ID: 27668569
[TBL] [Abstract][Full Text] [Related]
10. [Efficacy of 5-reductase inhibitors in the treatment of lower urinary tract symptoms in patients with benign prostatic hyperplasia].
Nizov AN
Urologiia; 2019 Dec; (5):156-160. PubMed ID: 31808653
[TBL] [Abstract][Full Text] [Related]
11. What are the predicting factors for the therapeutic effects of dutasteride in male patients with lower urinary tract symptoms? Investigation using a urodynamic study.
Matsukawa Y; Kato M; Funahashi Y; Majima T; Yamamoto T; Gotoh M
Neurourol Urodyn; 2017 Sep; 36(7):1809-1815. PubMed ID: 28102554
[TBL] [Abstract][Full Text] [Related]
12. Early effect of dutasteride added to alpha-1 blocker therapy for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia.
Araki K; Naya Y; Inahara M; Suzuki F; Ota S; Tsuji H; Mikami K; Yanagisawa M; Awa Y; Suzuki H
Int J Urol; 2014 Aug; 21(8):815-9. PubMed ID: 24735081
[TBL] [Abstract][Full Text] [Related]
13. High Real-World Medication Adherence and Durable Clinical Benefit in Medicare Patients Treated with 5-Alpha Reductase Inhibitors for Benign Prostatic Hyperplasia.
Zhang H; Frendl DM; Wang Z; Olumi AF
J Urol; 2020 Aug; 204(2):325-331. PubMed ID: 32167867
[TBL] [Abstract][Full Text] [Related]
14. Contemporary issues with pharmacotherapy for lower urinary tract symptoms.
Osman N; Chapple CR
Int J Clin Pract; 2014 May; 68(5):541-2. PubMed ID: 24750526
[TBL] [Abstract][Full Text] [Related]
15. Change in sexual function in men with lower urinary tract symptoms/benign prostatic hyperplasia associated with long-term treatment with doxazosin, finasteride and combined therapy.
Fwu CW; Eggers PW; Kirkali Z; McVary KT; Burrows PK; Kusek JW
J Urol; 2014 Jun; 191(6):1828-34. PubMed ID: 24342143
[TBL] [Abstract][Full Text] [Related]
16. Editorial comment to Early effect of dutasteride added to alpha-1 blocker therapy for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia.
Maeda T
Int J Urol; 2014 Aug; 21(8):819-20. PubMed ID: 24942824
[No Abstract] [Full Text] [Related]
17. The effects of dutasteride and finasteride on BPH-related hospitalization, surgery and prostate cancer diagnosis: a record-linkage analysis.
Cindolo L; Fanizza C; Romero M; Pirozzi L; Autorino R; Berardinelli F; Schips L
World J Urol; 2013 Jun; 31(3):665-71. PubMed ID: 23239103
[TBL] [Abstract][Full Text] [Related]
18. Clinical practice. Benign prostatic hyperplasia and lower urinary tract symptoms.
Sarma AV; Wei JT
N Engl J Med; 2012 Jul; 367(3):248-57. PubMed ID: 22808960
[No Abstract] [Full Text] [Related]
19. Pathophysiology of Benign Prostatic Hyperplasia and Benign Prostatic Enlargement: A Mini-Review.
Madersbacher S; Sampson N; Culig Z
Gerontology; 2019; 65(5):458-464. PubMed ID: 30943489
[TBL] [Abstract][Full Text] [Related]
20. Influence of dutasteride treatment on serum hormone levels and aging male symptoms in patients with benign prostatic enlargement.
Maeda T; Kikuchi E; Hasegawa M; Homma K; Ando T; Suzuki K; Kaneko G; Mizuno R; Miyajima A; Oya M
Int J Urol; 2018 Jan; 25(1):70-74. PubMed ID: 28975673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
